CT-P13 SC for the treatment of rheumatoid arthritis

References

• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 Feb 8;4:18001.
   PubMed Web of Science ®Google Scholar
• Markusse IM, Akdemir G, Dirven L, et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann Intern Med. 2016 Apr 19;164(8):523–531.
   PubMed Web of Science ®Google Scholar
• Malemba JJ, Mbuyi-Muamba JM, Mukaya J, et al. The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo–a population-based study. Rheumatology (Oxford). 2012 Sep;51(9):1644–1647.
   PubMed Web of Science ®Google Scholar
• Malemba JJ, Mbuyi-Muamba JM, Mukaya J, et al. The phenotype and genotype of rheumatoid arthritis in the Democratic Republic of Congo. Arthritis Res Ther. 2013 Aug 19;15(4):R89.
   PubMed Web of Science ®Google Scholar
• Ugarte-Gil MF, Silvestre AM, Pons-Estel BA. Access to an optimal treatment. Current situation. Clin Rheumatol. 2015 Mar;34 Suppl 1(Suppl1):S59–66.
   PubMedGoogle Scholar
• Misra DP, Sharma A, Agarwal V. Rheumatology science and practice in India. Rheumatol Int. 2018 Sep;38(9):1587–1600.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Song YW, Li ZG. Rheumatology in East Asia. Arthritis Res Ther. 2018 Mar 23;20(1):58.
   PubMedGoogle Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):685–699.
   PubMed Web of Science ®Google Scholar
• Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.Ann. Rheum Dis. 2021 Jan;80(1):71–87.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Haavardsholm EA, Rudin A, et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020 Dec;2(371):m4328.
   Google Scholar
• Akdemir G, Heimans L, Bergstra SA, et al. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. Ann Rheum Dis. 2018 Jan;77(1):111–118.
   PubMed Web of Science ®Google Scholar
• Stouten V, Westhovens R, Pazmino S, et al. Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. Ann Rheum Dis. 2021 Apr 2;annrheumdis-2020-219825. DOI:https://doi.org/10.1136/annrheumdis-2020-219825.
   Google Scholar
• Lau CS, Chia F, Dans L, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019 Mar;22(3):357–375.
   PubMed Web of Science ®Google Scholar
• Desai SP, Leatherwood C, Forman M, et al. Treat-to-target approach in rheumatoid arthritis: a quality improvement trial. Arthritis Care Res (Hoboken). 2021 Feb;73(2):207–214.
   PubMed Web of Science ®Google Scholar
• Humby F, Durez P, Buch MH, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021 Jan 23;397(10271):305–317.
   PubMed Web of Science ®Google Scholar
• Verschueren K, Van Essche E, Verschueren P, et al. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007 Nov;26(11):1969–1971.
   PubMed Web of Science ®Google Scholar
• Keersmaekers T, Claes K, Kuypers DR, et al. Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. Ann Rheum Dis. 2009 May;68(5):759–761.
   PubMed Web of Science ®Google Scholar
• Pope JE. Editorial: safety of tumor necrosis factor inhibitors in pregnancy. Arthritis Rheumatol. 2018 Sep;70(9):1359–1363.
   PubMed Web of Science ®Google Scholar
• Manders SH, Kievit W, Adang E, et al. Cost-effectiveness of Abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther. 2015;17(1):134.
   PubMedGoogle Scholar
• https://www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis 2021 Jun 7.
   Google Scholar
• Conaghan PG, Mysler E, Tanaka Y, et al. Upadacitinib in rheumatoid arthritis: a benefit-risk assessment Across a phase III program. Drug Saf. 2021 May;44(5):515–530.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017 Aug;76(8):1426–1431.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019 Feb;78(2):192–200.
   PubMed Web of Science ®Google Scholar
• Grøn KL, Glintborg B, Nørgaard M, et al. Comparative effectiveness of certolizumab pegol, abatacept, and biosimilar infliximab in patients with rheumatoid arthritis treated in Routine care: observational data from the Danish DANBIO registry emulating a randomized trial. Arthritis Rheumatol. 2019 Dec;71(12):1997–2004.
   PubMed Web of Science ®Google Scholar
• Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of Adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015 Feb;742:354–360. Epub 2013 Nov 27
   PubMed Web of Science ®Google Scholar
• Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007 Sep;66(9):1233–1238.
   PubMed Web of Science ®Google Scholar
• van Schouwenburg AP, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013 Mar;9(3):164–172.
   PubMed Web of Science ®Google Scholar
• Vander Cruyssen B, Durez P, Westhovens R, et al. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. Arthritis Res Ther. 2010;12(3):R77.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Vermeire S, Ballet V, et al. Switch to Adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2012 Feb;61(2):229–234.
   PubMed Web of Science ®Google Scholar
• Ulijn E, Den Broeder N, Wientjes M, et al. Therapeutic drug monitoring of Adalimumab in RA: no predictive value of Adalimumab serum levels and anti-Adalimumab antibodies for prediction of response to the next bDMARD. Ann Rheum Dis. 2020 Jul;79(7):867–873.
   PubMed Web of Science ®Google Scholar
• Syversen SW, Goll GL, Jørgensen KK, et al. Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021 May 4;325(17):1744–1754.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Houssiau F, Joly J, et al. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. J Rheumatol. 2006 May;33(5):847–853.
   PubMed Web of Science ®Google Scholar
• Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. MAbs. 2014;6(5):1163–1177.
   PubMed Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun 10;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Yoo DH, Schreiber S, et al. Subcutaneous administration of a novel formulation of CT-P13 (infliximab biosimilar) is safe and achieves projected therapeutic drug levels: a Phase I study in healthy subjects. United European Gastroenterol J. 2017;5:A297.
   Google Scholar
• Reinisch W, Jang BI, Borzan V, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase I open-label randomised controlled trial in patients with active Crohn’s disease. J Crohns Colitis. 2019;13(Supplement_1):S066–S067.
   Google Scholar
• Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized controlled trial: subcutaneous vs intravenous Infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021 Jun;160(7):2340–2353.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Jaworski J, Matyska-Piekarska E, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year results from a part 1 of phase I/III randomized controlled trial in patients with active rheumatoid arthritis. Ann Rheum Dis. 2019;78:733.
   Web of Science ®Google Scholar
• Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology (Oxford). 2021 May 14;60(5):2277–2287.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Ben-Horin S, Ye BD, et al. Development of a novel auto-injector of subcutaneous CT-P13 infliximab: phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects. J Crohns Colitis. 2019;13(Supplement_1):S458–S459.
   Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–1588.
   PubMed Web of Science ®Google Scholar
• Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011 Jan;9(1):2.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Westhovens R, Wiland P, et al. Impact of body mass index on clinical response of novel subcutaneous infliximab (CT-P13 SC) in patients with active rheumatoid arthritis:1 year results from a part 2 of phase I/III randomized control trial. Ann Rheum Dis. 2020;79(1):307.
   PubMedGoogle Scholar
• Westhovens R, Yoo DH, Wiland P, et al. Clinical evaluation of the immunogenicity to CT-P13 for subcutaneous use in patients with active rheumatoid arthritis: 1-year clinical results from a multicenter randomized controlled pivotal trial. Ann Rheum Dis. 2020;79(1):306.
   Google Scholar
• Caporali R, Allanore Y, Alten R, et al. Efficacy and safety of subcutaneous infliximab versus Adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert Rev Clin Immunol. 2021 Jan;17(1):85–99.
   PubMed Web of Science ®Google Scholar
• Combe B, Allanore Y, Alten R, et al. Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. Arthritis Res Ther. 2021 Apr 16;23(1):119.
   PubMed Web of Science ®Google Scholar
• [cited 2021 Jun 7]. Available from:https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf
   Google Scholar
• [cited 2021 Jun 7]. Available from:https://www.biosimilardevelopment.com/doc/european-commission-grants-marketing-authorisation-for-world-s-first-subcutaneous-0001
   Google Scholar
• [cited 2021 Jun 7]. Available from:https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/v2c_ea_v__10_2003_en.pdf
   Google Scholar
• Kim H, Alten R, Cummings F, et al. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs. 2021 Jan-Dec;13(1):1868078.
   PubMed Web of Science ®Google Scholar